Ribociclib lee011

MCF7 cells were treated with different concentrations (100 nM, 200 nM, 500 nM or 1000 nM) of Palbociclib (PD0332991) (APExBIO), Abemaciclib (LY2835219) (Selleckchem) or Ribociclib (LEE011) (Selleckchem) and the other cancer cell lines with the indicated concentration of inhibitor. Media was changed every 2 days. Human primary fibroblasts (HFFF2) were treated with 50μM of Etoposide (Sigma-Aldrich) for 2 days and cells collected at day 7 or treated with 1μM Palbociclib for 7 days. HFFF2 expressing pLNC-ER:RAS vector, were induced to senescence by adding 200 nM 4-hydroxytamoxifen (4OHT) (Sigma-Aldrich) for 6 days. All treatments were done using DMEM supplemented with 10% FBS and 1% of antibiotic-anti-mycotic. HUVEC cells were treated with 500 nM Palbo for 7 days to induce senescence.

Palbociclib (PD-0332991) (Selleck Chem S1116), Ribociclib (LEE011) (Selleck Chem S7440), and Abemaciclib (LY2835219) (Selleck Chem S7158) were used at a concentration of 6 µM for FRAP experiments. Palbociclib and Ribociclib were used at a concentration of 3 µM for live-cell CDK2 activity experiments in MCF-10A cells.